Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam S Cheifetz

Showing results (1-10 of 202) with videos related to

Pageof 21
Sort By:
JAMA|May 23, 2013
Management of active Crohn diseaseAdam S Cheifetz
Inflammatory Bowel Diseases|October 9, 2004
You say goodbye and I say aloeAdam S Cheifetz
Journal of Crohn'S & Colitis|February 14, 2016
Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's DiseaseKonstantinos Papamichael, Adam S Cheifetz
Gastroenterology|August 11, 2019
Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?Konstantinos Papamichael, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 23, 2013
The holistic effects of cannabis in Crohn's diseaseConor Lahiff, Adam S Cheifetz
Digestive Diseases and Sciences|March 31, 2019
Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD TherapyKonstantinos Papamichael, Adam S Cheifetz
Current Opinion in Rheumatology|May 16, 2020
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterologyKonstantinos Papamichael, Adam S Cheifetz
Inflammatory Bowel Diseases|July 22, 2015
Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency DepartmentLaurie Gashin, Adam S Cheifetz
The Journal of Rheumatology|August 4, 2012
Infusion reactions related to infliximab therapy are not usually associated with drug discontinuationGarrett Cullen, Adam S Cheifetz
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2022
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodiesKonstantinos Papamichael, Adam S Cheifetz
Pageof 21

Showing results (1-10 of 202) with videos related to

Sort By:
Pageof 21
JAMA|May 23, 2013
Management of active Crohn diseaseAdam S Cheifetz
Inflammatory Bowel Diseases|October 9, 2004
You say goodbye and I say aloeAdam S Cheifetz
Journal of Crohn'S & Colitis|February 14, 2016
Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's DiseaseKonstantinos Papamichael, Adam S Cheifetz
Gastroenterology|August 11, 2019
Is It Prime Time for Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease?Konstantinos Papamichael, Adam S Cheifetz
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 23, 2013
The holistic effects of cannabis in Crohn's diseaseConor Lahiff, Adam S Cheifetz
Digestive Diseases and Sciences|March 31, 2019
Integrin Calculus: The Predictive Power of Vedolizumab Concentrations in IBD TherapyKonstantinos Papamichael, Adam S Cheifetz
Current Opinion in Rheumatology|May 16, 2020
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterologyKonstantinos Papamichael, Adam S Cheifetz
Inflammatory Bowel Diseases|July 22, 2015
Reply to Use of CT Scan in Ulcerative Colitis Patients Presenting to the Emergency DepartmentLaurie Gashin, Adam S Cheifetz
The Journal of Rheumatology|August 4, 2012
Infusion reactions related to infliximab therapy are not usually associated with drug discontinuationGarrett Cullen, Adam S Cheifetz
Expert Opinion on Drug Metabolism & Toxicology|January 8, 2022
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodiesKonstantinos Papamichael, Adam S Cheifetz
Pageof 21